Beijing Hanmi Pharmaceutical Co., Ltd.

Hanmi Pharmaceutical reschedules efpeglenatide launch to 2H 2026, aiming for 100 billion won annual sales. The anti-obesity drug, in Phase 3 trials, targets overweight and stage 1 obese individuals, promising weight-loss effects similar to Wegovy with enhanced cardiovascular and kidney benefits. Developed with Lapscovery tech, it reduces GI side effects. A digital combination drug integrating efpeglenatide with digital therapeutics is also in development for personalized obesity management.

Hanmi Pharmaceutical accelerates launch of obesity drug Efeglenatide to 2H 2026, designed for overweight and stage 1 obesity patients with improved gastrointestinal tolerability and potential cardiovascular and renal benefits. Part of the Holistic Obesity Program (HOP), it includes triple-action treatment HM15275 with Phase 1 trials in the US, aiming for Phase 2 in 2H 2025. Hanmi also develops oral drugs, micro-needle patches, and inhalable powders to combat global obesity.

Curocell appoints Lee Seung-won as managing director to lead domestic commercialization of next-gen CAR-T treatment CRC01 (Anbal-cel). Lee, with 20+ years in hematologic cancers and CAR-T therapeutics, aims to expedite Anbal-cel's approval and global expansion.

Bridge Biotherapeutics, Daewoong, and Ildong Pharmaceutical lead in IPF treatment development, with Bridge's BBT-877 in Phase 2 trials targeting autotaxin. Daewoong's Versiporocin aims to reduce PRS protein action, while Ildong's IL1512 targets CXCR7. Hanmi's HM15211, initially for MASH, shows IPF efficacy. Boehringer Ingelheim's Nerandomilast met primary trial endpoints, but side effects are a concern.

MEDiC Life Sciences secures $5M from LG and Hanmi Pharmaceutical, accelerating cancer biomarker discovery via MCAT platform, enhancing drug efficacy and market potential. The investment aims to bolster business development and advance drug discovery efforts, positioning MEDiC as a leader in functional genomics for solid tumors.

Hanmi Pharmaceutical's six new drugs for hypertension, dyslipidemia, diabetes, and musculoskeletal system are in phase 1-3 clinical trials. HCP1803, a low-dose triple antihypertensive, is progressing in phase 3 trials in Korea, with results presented at the ESH congress. The company launched diabetes and antithrombotic drugs, and its biologic Rolvedon generated significant sales. Hanmi is also developing a Korean-specific GLP-1 obesity drug and aims to be a global R&D-centered pharmaceutical company.

Novo Nordisk's obesity drug WeGovi to be released in Korea on Oct 15, with a factory price of 370,000 won, not covered by health insurance; patients' actual cost around 800,000 won. Administered weekly via injection, it targets patients with BMI 30+ or those with obesity-related diseases (BMI 27-30). Expected to significantly impact the 180 billion won domestic obesity drug market.

GC Biopharma and Hanmi Pharmaceutical's Fabry treatment 'LA-GLA' received FDA IND clearance for a Phase 1/2 trial, aiming to evaluate safety and efficacy as the world's first once-monthly subcutaneous treatment, improving kidney function, vascular disease, and peripheral nerve disorders.